Overview
- A coalition of 48 states and territories reached the $29.6 million deal with Glenmark to resolve claims that the company conspired with competitors to inflate prices and limit competition in the generic drug market.
- Under the agreement Glenmark will cooperate with ongoing multistate litigation against dozens of other manufacturers and executives and adopt internal antitrust compliance measures.
- Consumers who bought certain generic drugs made by Glenmark, Lannett, Bausch, Apotex, or Heritage between May 1, 2009 and December 31, 2019 can seek payment through a centralized claims process by calling 1-866-290-0182, emailing info@AGGenericDrugs.com, or visiting AGGenericDrugs.com.
- The settlement was announced July 15–16, 2026 and follows earlier agreements with Lannett, Bausch, Apotex and Heritage that together total about $66.95 million, while trials against other defendants are still pending.
- State prosecutors say their case rests on cooperating witnesses, a document database of over 20 million items and millions of call-detail records that show industry coordination at dinners, golf outings and in messages using phrases like 'fair share' to police pricing.